enGene Therapeutics (ENGN) Assets (2022 - 2026)
enGene Therapeutics (ENGN) posted quarterly Assets of $307.5 million for Q2 2026, up 15.33% year-over-year from $266.7 million in Q2 2025, and down 8.78% quarter-over-quarter from $337.1 million in Q1 2026.
enGene Therapeutics (ENGN) Assets (2022 - 2026) Analysis & Trends
enGene Therapeutics (ENGN) has reported Assets for 5 consecutive years, with $307.5 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Assets rose 15.33% year-over-year to $307.5 million; the TTM figure through Apr 2026 stood at $307.5 million (up 15.33% YoY), while the FY2025 annual figure was $221.5 million, down 28.83% from the prior year.
- Assets slipped to $307.5 million in Q2 2026 per ENGN's latest filing, from $337.1 million in the prior quarter.
- Across five years, Assets topped out at $337.1 million in Q1 2026 and bottomed at $23.9 million in Q4 2022.
- Historically, Assets has averaged $226.7 million across 5 years, with a median of $266.8 million in 2024.
- Annual changes were most pronounced in 2023 — Assets surged 263.71% — and 2025, when it decreased 28.83%.
- enGene Therapeutics' Assets stood at $23.9 million in 2022, then soared by 263.71% to $87.0 million in 2023, then jumped by 257.84% to $311.2 million in 2024, then fell by 28.83% to $221.5 million in 2025, then soared by 38.86% to $307.5 million in 2026.
- Business Quant data shows ENGN's Assets at $307.5 million in Q2 2026, $337.1 million in Q1 2026, and $221.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.56 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.10 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.60 Bn |
| 10 | enGene Therapeutics | 124.11 Mn | 124.11 Mn | - | 307.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 307.52 Mn |
| Jan 31, 2026 | 337.11 Mn |
| Oct 31, 2025 | 221.47 Mn |
| Jul 31, 2025 | 245.55 Mn |
| Apr 30, 2025 | 266.65 Mn |
| Jan 31, 2025 | 285.93 Mn |
| Oct 31, 2024 | 311.17 Mn |
| Jul 31, 2024 | 266.88 Mn |
| Apr 30, 2024 | 273.53 Mn |
| Jan 31, 2024 | 93.42 Mn |
| Oct 31, 2023 | 86.96 Mn |
| Oct 31, 2022 | 23.91 Mn |